Ascend Wellness: Canaccord Lowers Target To US$10

On January 14th, after a number of press releases from Ascend Wellness Holdings, Inc. (CSE: AAWH.U), the company finally announced that it has filed a complaint against MedMen Enterprises Inc. (CSE: MMEN) and a preliminary injunction against them. This is in regards to Medmen’s unwillingness to transfer their New York license to Ascend.

Ascend Wellness currently has 8 analysts covering the stock with an average 12-month price target of US$13.19, or a 140% upside to the current stock price. Out of the 8 analysts, 2 have strong buy ratings while the other 6 have buy ratings. The street high sits at US$18, or a 228% upside to the current stock price, while the lowest price target sits at US$10.

In Canaccord Genuity’s update note, they reiterate their buy rating but lower their 12-month price target from US$13 to US$10 after reducing their Illinois and New Jersey estimates.

Canaccord has lowered its fourth-quarter estimates to $86.1 million in revenue and $19 million in adjusted EBITDA, putting the full-year estimates at $330 million and $78.7 million for revenue and adjusted EBITDA, respectively. They say that this revision primarily comes from “pricing pressure and a later-than-anticipated planting in IL, and a slower start to rec benefits in NJ.”

On the lawsuit, although Canaccord does not include any contributions from New York in their full-year estimates, they view that this asset is attractive and could possibly drive 5-10% of sales once integrated.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

Haywood Reiterates $12 Price Target On Well Health

On January 20th, Well Health (TSX: WELL) provided a business update which included fourth quarter...

Monday, January 24, 2022, 04:22:00 PM

K92 Mining: Canaccord Reiterates $12 Price Target Following Bought Deal

K92 Mining Inc. (TSX: KNT) announced a $50 million bought deal this past week, selling...

Sunday, June 19, 2022, 11:12:00 AM

IAMGOLD: BMO Lowers Price Target After Disappointing Guidance

On January 12th, IAMGOLD Corp (TSX: IMG) announced its preliminary 2021 operational results and 2022...

Friday, January 14, 2022, 03:36:00 PM

Lululemon: BMO Cuts Target To $304 Following Q1 Beat Due To Inflationary Pressures

On Thursday, Lululemon Athletica Inc. (Nasdaq: LULU) reported its first-quarter financial results for 2022. The...

Saturday, June 4, 2022, 05:20:00 PM

Boeing Sees Canaccord Reiterate Price Target, Buy Rating

In the last weeks, Boeing (NYSE: BA) has been in the news due to its...

Wednesday, July 21, 2021, 02:13:00 PM